Adamas Pharmaceuticals (ADMS) Misses Q3 EPS by 13c
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q3 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).
For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- RCM Technologies (RCMT) Tops Q2 EPS by 17c
- Marpai, Inc. (MRAI) Misses Q2 EPS by 18c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
